Sign in
Taking people in United StatesPhase 2

Weight loss plus progestin to preserve the uterus in women with endometrial disease

Tests weight-loss coaching with progestin in women with obesity and early uterine disease.

Key facts

Who runs it
Washington University School of Medicine
Where
Albuquerque, Oklahoma City, and St Louis, United StatesSee the 3 sites
Trial code
Registry title
Uterine Preservation Via Lifestyle Transformation
Status
Recruiting
Phase
Phase 2
People taking part
96 people, planned
Started
24 Oct 2024
Expected to end
31 Oct 2029
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Telemedicine behavioral weight intervention
  • Progestin
  • Enhanced usual care
  • Levonorgestrel-releasing IUD.
Record updated
20 January 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for premenopausal women aged 18 to 45 with obesity and atypical endometrial hyperplasia or grade 1 endometrial cancer, who want to keep their uterus.

Age
18 to 45 years
Sex
Women only
Disease stage
Complex atypical endometrial hyperplasia (AEH) or grade 1 endometrial cancer, confirmed by tissue examination. Performance status (ECOG) 0-2.
Earlier treatment
People already on oral or LNG-IUD progestin treatment can join. They must be willing to have an LNG-IUD placed at study entry.
Biomarker or test result
BMI of 30 kg/m^2 or higher.

Main reasons for not taking part

  • Current chemotherapy or radiation for any cancer
  • Pregnant or breastfeeding
  • Active pelvic infection at the time of IUD placement
  • Any other reason the doctor judges an IUD cannot be used

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Diagnosis of histologically confirmed complex atypical endometrial hyperplasia (AEH) or grade 1 endometrial cancer; Patients with a previous diagnosis of AEH or grade 1 endometrial cancer who are already being followed with conservative management with oral or LNG-IUD progestin therapy are eligible; For patients with a previous diagnosis of AEH or grade 1 endometrial cancer who have been placed on progestin prior to study entry, the duration of IUD or oral progestin use prior to trial entry should be documented
  • Premenopausal woman with a uterus
  • ECOG performance status of 0-2
  • At least 18 years of age and no more than 45 years of age
  • Undergoing uterine-sparing management (e.g. due to interest in fertility preservation, interest in uterine preservation, provider recommendation, or other reason)
  • BMI ≥ 30 kg/m\^2
  • Prior or current receipt of progestin is allowed as above. Willingness to undergo placement of LNG-IUD at the time of study entry
  • Ability to understand and willingness to sign an IRB approved written informed consent document

Who cannot take part

  • Current, active treatment for any malignant neoplasm with chemotherapy or radiation
  • Active pelvic infection at the time of IUD placement or other contraindication to the use of an IUD in the opinion of the treating physician
  • Pregnant and/or breastfeeding. Participants must have a negative urine or serum pregnancy test during screening window and within 7 days prior to LNG-IUD insertion. If LNG-IUD is in place, lack of pregnancy is assumed

Where in United States

  • University of New MexicoAlbuquerque, United StatesContact: Carolyn Muller, M.D.Taking people
  • University of OklahomaOklahoma City, United StatesContact: Kathleen Moore, M.D., MSTaking people
  • Washington University School of MedicineSt Louis, United StatesContact: Andrea R Hagemann, M.D., MSCITaking people

About the trial

What the trial wants to find out

Up to 60% of endometrial cancer cases are attributed to obesity, in part because obesity promotes development of atypical endometrial hyperplasia (AEH), and up to 40% of women with AEH go on to develop endometrial cancer. The increasing prevalence of obesity in premenopausal women has resulted in increasing rates of AEH in this age group. Hysterectomy with removal of the fallopian tubes and ovaries is 100% effective in preventing endometrial cancer, but this approach results in infertility. Fertility-sparing treatments exist, such as treatment with oral or intrauterine progestin, but these treatments do not work uniformly and do not combat the underlying cause of endometrial cancer, which is obesity and metabolic syndrome. Additionally, up to 41% of women on progestin eventually experience relapse of AEH or endometrial cancer. Third, many patients have insulin resistance that may worsen with progestin therapy. Thus, to improve treatment of AEH and grade 1 endometrial cancer, prevent and reverse endometrial cancer, and allow women to preserve their fertility, the investigators must integrate an effective weight loss strategy to be given with progestin treatment. It is the hypothesis that premenopausal women with AEH desire uterine preservation will be more likely to have atypia-free uterine preservation at one year if they receive progestin in combination with a behavioral weight loss intervention versus progestin plus enhanced usual care.

The 2 groups in the trial

  • Arm 1: Levonorgestrel-releasing IUD (LNG-IUD) + Behavioral Weight Loss InterventionTreatment being tested

    * The levonorgestrel-releasing IUD is used in this study as per standard care. * The behavioral weight loss intervention consists of a telemedicine cognitive behavioral coaching program. At each session, patients will self-report weight, number of days they kept a food journal during the past week, average daily caloric intake for the week, number of days exercised for the week, total number of minutes of moderate physical activity, and average number of steps per day for the week.

    Treatment: Telemedicine behavioral weight intervention, Progestin, and Levonorgestrel-releasing IUD.

  • Arm 2: Levonorgestrel-releasing IUD (LNG-IUD) + Enhanced Usual CareExisting treatment, for comparison

    * The levonorgestrel-releasing IUD is used in this study as per standard care. * Participants will be provided with 1- to 3-page handouts on topics including healthy eating, exercise, and behavioral eating strategies from materials provided on the American Cancer Society, Society of Gynecologic Oncology, and WebMD Nourish websites. These materials encourage weight loss through calorie counting, recording dietary intake, engaging in exercise programs, and using portion control strategies. * The participants randomized to this arm will cross over to the behavioral weight loss intervention arm at 12 months if they have not achieved resolution of AEH or grade 1 endometrial cancer.

    Treatment: Enhanced usual care and Levonorgestrel-releasing IUD.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
UPLifT-Endo: Uterine Preservation Via Lifestyle Transformation A Behavioral Intervention to Promote Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Atypical Endometrial Hyperplasia or Grade 1 Endometrial Cancer
Plain-language title
Weight loss plus progestin to preserve the uterus in women with endometrial diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
20 January 2026